Idera Pharma Opens Enrollment For Phase 1/2 Trial Of IMO-8400 - Quick Facts

(RTTNews) - Idera Pharmaceuticals, Inc. (IDRA), a clinical stage biopharmaceutical company, announced that enrollment is open for a Phase 1/2 clinical trial of IMO-8400 in patients with Waldenström's macroglobulinemia, following acceptance of its IND application by the FDA. The objectives of the trial are to evaluate the compound's safety, tolerability, and potential clinical activity.

The trial will enroll patients with Waldenström's macroglobulinemia who have a history of relapse or failure to respond to one or more prior therapies. Idera expects to enroll a total of approximately 30 patients.